IL1B and breast cancer: MCF-7 Human breast cancer cells [13] were treated with different concentrations of CCL21/IL1β recombinant protein, non-recombinant protein as the negative control, CCL21 commercial protein as the positive control, and also DMEM high glucose culture medium as the control, for 24, 48, and 72 hours to investigate the cytotoxicity of CCL21/IL1β using the MTT test.